Adrienne Landsteiner

Adrienne Landsteiner

Auto-generated profile, based on publicly available information

Adrienne Landsteiner

Minneapolis VAHCS: Minneapolis VA Medical Center

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2024 in Annals of Internal Medicine
Verified
Journal Article
Closed access
TDTyler Drake
Tyler Drake
ALAdrienne Landsteiner
Adrienne Landsteiner
LLLisa Langsetmo
Lisa Langsetmo
RMRoderick MacDonald
Roderick MacDonald
MAMaylen Anthony
Maylen Anthony
TWTimothy J. Wilt
Timothy J. Wilt
Newer diabetes medications may have beneficial effects on mortality, cardiovascular outcomes, and renal outcomes. To evaluate the effectiveness, comparative effectiveness, and harms of sodium-glucose cotransporter-2 (SGLT2) inhibitors, glucagon-like peptide-1 (GLP1) agonists, dipeptidyl peptidase-4 (DPP4) inhibitors, and long-acting insulins as monotherapy or combination therapy in adults with type 2 diabetes mellitus (T2DM). MEDLINE and EMBASE for randomized controlled trials (RCTs) published from 2010 through January 2023. RCTs lasting at least 52 weeks that included at least 500 adults with T2DM receiving eligible medications and reported any outcomes of interest. Data were abstracted by 1 reviewer and verified by a second. Independent, dual assessments of risk of bias and certainty of evidence (CoE) were done. A total of 130 publications from 84 RCTs were identified. CoE was appraised using GRADE (Grading of Recommendations Assessment, Development and Evaluation) criteria for direct, indirect, and network meta-analysis (NMA); the highest CoE was reported. Compared with usual care, SGLT2 inhibitors and GLP1 agonists reduce all-cause mortality (high CoE) and major adverse cardiovascular events (MACE) (moderate to high CoE), SGLT2 inhibitors reduce progression of chronic kidney disease (CKD) and heart failure hospitalizations and GLP1 agonists reduce stroke (high CoE), and SGLT2 inhibitors reduce serious adverse events and severe hypoglycemia (high CoE). The threshold for minimally important differences, which was predefined with the American College of Physicians Clinical Guidelines Committee, was not met for these outcomes. Compared with usual care, insulin, tirzepatide, and DPP4 inhibitors do not reduce all-cause mortality (low to high CoE). Compared with insulin, SGLT2 inhibitors and GLP1 agonists reduce all-cause mortality (low to moderate CoE). Compared with DPP4 inhibitors, GLP1 agonists reduce all-cause mortality (moderate CoE). Compared with DPP4 inhibitors and sulfonylurea (SU), SGLT2 inhibitors reduce MACE (moderate to high CoE). Compared with SU and insulin, SGLT2 inhibitors and GLP1 agonists reduce severe hypoglycemia (low to high CoE). Infrequent direct comparisons between drugs of interest; sparse data for NMA on most outcomes; possible incoherence due to differences in baseline patient characteristics and usual care; insufficient data on predefined subgroups, including demographic subgroups, patients with prior cardiovascular disease, and treatment-naive persons. In adults with T2DM, SGLT2 inhibitors and GLP1 agonists (but not DPP4 inhibitors, insulin, or tirzepatide) reduce all-cause mortality and MACE compared with usual care. SGLT2 inhibitors reduce CKD progression and heart failure hospitalization and GLP1 agonists reduce stroke compared with usual care. Serious adverse events and severe hypoglycemia are less frequent with SGLT2 inhibitors and GLP1 agonists than with insulin or SU. American College of Physicians. (PROSPERO: CRD42022322129).

1 May 2024 in Annals of Internal Medicine
Verified
Journal Article
Closed access
JSJohn T. Schousboe
John T. Schousboe
ALAdrienne Landsteiner
Adrienne Landsteiner
TDTyler Drake
Tyler Drake
SSShahnaz Sultan
Shahnaz Sultan
LLLisa Langsetmo
Lisa Langsetmo
TWTimothy J. Wilt
Timothy J. Wilt
In the United States, costs of antidiabetes medications exceed $327 billion. To systematically review cost-effectiveness analyses (CEAs) of newer antidiabetes medications for type 2 diabetes. Bibliographic databases from 1 January 2010 through 13 July 2023, limited to English. Nonindustry-funded CEAs, done from a U.S. perspective that estimated cost per quality-adjusted life-year (QALY) gained for newer antidiabetic medications. Two reviewers screened the literature; disagreements were resolved with a third reviewer. Cost-effectiveness analyses were reviewed for treatment comparisons, model inputs, and outcomes. Risk of bias (RoB) of the CEAs was assessed using Drummond criteria and certainty of evidence (CoE) was assessed using GRADE (Grading of Recommendations Assessment, Development, and Evaluations). Certainty of evidence was determined using cost per QALY thresholds predetermined by the American College of Physicians Clinical Guidelines Committee; low (>$150 000), intermediate ($50 to $150 000), or high (<$50 000) value per QALY compared with the alternative. Nine CEAs were eligible (2 low, 1 high, and 6 some concerns RoB), evaluating glucagon-like peptide-1 agonists (GLP1a), dipeptidyl peptidase-4 inhibitors (DPP4i), sodium-glucose cotransporter-2 inhibitors (SGLT2i), glucose-dependent insulinotropic peptide agonist (GIP/GLP1a), and insulin. Comparators were metformin, sulfonylureas, neutral protamine Hagedorn (NPH) insulin, and others. Compared with metformin, GLP1a and SGLT2i are low value as first-line therapy (high CoE) but may be of intermediate value when added to metformin or background therapy compared with adding nothing (low CoE). Insulin analogues may be similarly effective but more expensive than NPH insulin (low CoE). The GIP/GLP1a value is uncertain (insufficient CoE). Cost-effectiveness analyses varied in methodological approach, assumptions, and drug comparisons. Risk of bias and GRADE method for CEAs are not well established. Glucagon-like peptide-1 agonists and SGLT2i are of low value as first-line therapy but may be of intermediate value when added to metformin or other background therapy compared with adding nothing. Other drugs and comparisons are of low or uncertain value. Results are sensitive to drug effectiveness and cost assumptions. American College of Physicians. (PROSPERO: CRD42022382315).

15 October 2025 in CHEST Pulmonary
Verified
Journal Article
Open access
ALAdrienne Landsteiner
Adrienne Landsteiner
NZNicholas Zerzan
Nicholas Zerzan
KUKristen E. Ullman
Kristen E. Ullman
MAMaylen Anthony
Maylen Anthony
ACAmy M. Claussen
Amy M. Claussen
TWTimothy J. Wilt
Timothy J. Wilt
Lung cancer screening (LCS) with annual low-dose CT scanning is recommended for eligible individuals. The Centers of Medicare and Medicaid Services stipulates that counseling and shared decision-making (SDM) are a prerequisite for LCS reimbursement; however, SDM effects and optimal strategies are poorly understood. What are the effects of LCS SDM tools and strategies? This was a systematic review of US-based randomized controlled trials or observational studies of LCS SDM with a comparator. We searched Embase and MEDLINE via Ovid and CINAHL via EbscoHost for dates January 2010 through December 2023. We used dual abstraction and risk-of-bias (RoB) assessment with Cochrane RoB 2.0 tool for randomized controlled trials and Joanna Briggs Institute RoB for observational studies. Certainty of evidence (CoE) was based on Grading of Recommendations, Assessment, Development, and Evaluation. Thirty-one studies were eligible. Studies varied in design, intervention, comparator, and methodology precluding quantitative analysis. Few reports provided adequate information to assess if they met Centers of Medicare and Medicaid Services SDM criteria. We summarized findings by whether the tool was a health care provider- or patient-facing tool or material. Few studies addressed uptake, adherence, and harms. SDM, including by care coordinators or patient navigators, may increase LCS participation with acceptable information quality (low CoE) and does not increase decisional conflict/regret (high CoE). The choice of SDM tool may not affect LCS uptake (low CoE). Little evidence exists on whether effects vary by patient or clinic characteristics. LCS SDM evidence is limited due to study variability and short follow-up. SDM may increase LCS participation, has acceptable information quality, and does not increase decisional conflict/regret. Most studies reported on knowledge; few addressed clinical and patient-centered outcomes. Specific SDM tool choice may not impact LCS. A decision aid may be superior to an education tool. Implementation should consider feasibility and that delivery included print, web, in-person, and video, with most patient-facing. International Prospective Register of Systematic Reviews; No.: CRD42024511257; URL: https://www.crd.york.ac.uk/prospero/.

25 September 2025 in JMIR Preprints
Verified
Preprint
Open access
CKCaleb Kalinowski
Caleb Kalinowski
EGElizabeth Goldsmith
Elizabeth Goldsmith
MAMaylen Anthony
Maylen Anthony
ALAdrienne Landsteiner
Adrienne Landsteiner
KUKristen Ullman
Kristen Ullman
DEDavid Ewart
David Ewart
BACKGROUND Non-pharmacologic interventions are important for treating knee pain due to osteoarthritis (OA) or after total knee arthroplasty (TKA). Extended reality (XR) technology may enhance the efficacy of non-pharmacologic treatments including rehabilitation for these indications, but a review of current evidence is needed to evaluate benefits and harms of XR-based interventions. OBJECTIVE We conducted a systematic review to assess benefits and harms of XR interventions for pain due to knee OA or recovery after TKA. METHODS We searched MEDLINE, Embase, CINHAL, PsycINFO, and Scopus databases from inception to May 2023. Eligible studies included randomized controlled trials (RCTs) that evaluated XR interventions to treat pain due to knee OA or after TKA and reported at least one eligible outcome (eg, pain-related functioning or interference, pain intensity, or adverse events). Risk of bias (RoB) was assessed using the Cochrane RoB 2 tool. Data were abstracted by one reviewer and verified by a second. We classified interventions as either virtual reality (VR, fully immersive) or augmented reality (AR, partially immersive). We used GRADE criteria to determine certainty of evidence (COE) for prioritized outcomes. RESULTS We identified eligible RCTs addressing pain due to knee OA (k=5) or recovery after TKA (k=7). All studies were rated some concerns (k=6) or high (k=6) RoB. Sample sizes ranged from 52-306 participants and most (k=8) had a follow-up of ≤3 months. Guiding and engaging physical activity was the primary mechanism of interventions in 11 of the studies and 1 study utilized distraction only. Ten studies assessed pain-related functioning and 11 assessed pain intensity or severity. Two assessed adverse events. In the knee OA group 1 study examined VR and 4 examined AR. Compared with conventional therapy, VR physical activity may result in better pain-related functioning and greater decreases in pain intensity (low COE); evidence is very uncertain on the effects of AR physical activity on pain-related functioning, pain intensity, and adverse events (very low COE). For post-TKA, 2 studies examined VR and 5 examined AR. Compared with standard rehabilitation, AR physical activity may result in better pain-related functioning (low COE), but evidence is very uncertain on its effects on pain intensity and adverse events. The evidence is very uncertain on the effects of VR physical activity on pain-related functioning and pain intensity. CONCLUSIONS Trials commonly evaluated XR interventions facilitating physical activity, and most often compared XR to standard, non-XR exercise or rehabilitation. Evidence on benefits and harms of XR interventions to treat pain in knee OA and post-TKA is limited due to methodological concerns, small study size, and lack of reporting on adverse events. Larger high-quality RCTs with longer follow-up are needed to improve understanding of benefits and harms of XR interventions in knee OA or post-TKA. CLINICALTRIAL PROSPERO registration number CRD42023439903

8 September 2026 in Journal of Medical Internet Research
Verified
Journal Article
Open access
CKCaleb Kalinowski
Caleb Kalinowski
EGElizabeth Goldsmith
Elizabeth Goldsmith
MAMaylen Anthony
Maylen Anthony
ALAdrienne Landsteiner
Adrienne Landsteiner
KUKristen Ullman
Kristen Ullman
DEDavid Ewart
David Ewart
Background: Nonpharmacologic interventions are important for treating knee pain due to osteoarthritis or after total knee arthroplasty (TKA), and extended reality (XR) technology may enhance treatments for these indications. Objective: This systematic review aimed to evaluate XR interventions for pain due to knee osteoarthritis (KOA) or for recovery after TKA. Methods: Databases were searched through May 2023 and updated in December 2025. Eligible trials evaluated XR interventions to treat KOA pain or after TKA. We classified interventions by depth of immersion and clinical mechanism. We used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) criteria to determine the certainty of evidence for prioritized outcomes. Meta-analyses were performed when ≥3 studies evaluated similar comparisons, outcomes, and time points. Results: Eligible trials addressed KOA (k=12) or recovery after TKA (k=9). Sample sizes ranged from 36 to 306 participants, and most studies had a follow-up of ≤3 months. Nineteen studies assessed pain-related functioning and pain intensity, and 5 assessed adverse events (AEs). For KOA, 10 studies examined interactive digital rehabilitation (IDR), and 2 examined virtual reality (VR)–digitally augmented exercise (DAE). IDR for KOA may result in better pain-related functioning (low certainty of evidence [COE]; pooled standardized mean difference [SMD] −0.59, 95% CI −1.11 to −0.06; prediction interval [PI] −1.72 to 0.55; k=5) and lower pain intensity at 6‐8 weeks (low COE; pooled SMD −0.46, 95% CI −0.92 to 0.00; PI −1.39 to 0.47; k=4). VR-DAE for KOA (k=2) produced inconsistent results (very low COE). For post-TKA studies, 5 examined IDR, 2 examined VR-DAE, 1 examined VR-distraction, and 1 examined VR-psychoeducation. Post-TKA IDR may result in better pain-related functioning (low [k=4] and moderate COE [k=1]) but little to no difference in pain intensity (low-moderate COE; pooled SMD at 3‐4 months −0.12, 95% CI −0.75 to 0.52; PI –1.63 to 1.27; k=3). VR-psychoeducation probably results in lower pain at 4 weeks (moderate COE; k=1), and VR-distraction may result in 6 months (low COE; k=1), whereas VR-DAE produced mixed findings (k=2; very low COE). IDR was not associated with AEs, and VR may not be associated with AEs for KOA (high and low COE), though AE reporting was uncommon (k=5) and evidence was very uncertain for post-TKA. Conclusions: IDR may augment treatment for KOA and post-TKA recovery, and VR may benefit post-TKA rehabilitation. This review is the first to stratify by level of immersion, clinical mechanism, and follow-up duration and to systematically evaluate AEs. IDR may be ready for integration into KOA care, while use after TKA needs more evidence. Randomized controlled trials with implementation outcomes could determine how XR interventions can be used for KOA, whereas trials evaluating efficacy and AEs are needed before their use for post-TKA.

11 June 2026 in Antimicrobial Stewardship & Healthcare Epidemiology
Verified
Journal Article
Open access
PDF file
ALAdrienne Landsteiner
Adrienne Landsteiner
MNMuthu Narayan
Muthu Narayan
JBJonathan Byrd
Jonathan Byrd
SYSteffi Yang
Steffi Yang
KUKristen Ullman
Kristen Ullman
WDWei Duan-Porter
Wei Duan-Porter
Objective: To describe the evidence on antimicrobial stewardship programs (ASPs) and strategies implemented in outpatient settings. Design: We conducted a scoping review to describe the evidence published since 2013 on the effects and implementation of outpatient ASP strategies and programs. Methods: We searched Ovid MEDLINE, Embase, and Scopus from January 1, 2013 through September 3, 2024. Data were summarized in figures and tables. We categorized studies by types of ASP strategies and settings. We also summarize the reported outcomes using the RE-AIM framework. Results: Of 29,544 unique citations/abstracts, 285 primary studies and 37 systematic reviews were eligible. Most included primary studies were observational ( k = 226) and only 59 (21%) were randomized controlled trials (RCT). Most studies were conducted in primary care ( k = 135) or emergency room/urgent care ( k = 79). The most commonly evaluated individual strategies were patient and/or clinician education only ( k = 55), audit and feedback ( k = 48), and laboratory testing ( k = 45). Overall antimicrobial and inappropriate prescribing rates were the most frequently assessed outcomes; patient treatment outcomes and health care utilization were also commonly reported. Conclusions: There has been substantial growth in the evidence base, but this is largely from observational studies. Evidence gaps include a need for more controlled studies, and evaluation of additional outcomes. Few studies evaluated implementation costs or barriers, reach, and sustainability. Many of these additional outcomes would provide valuable insights to aid policy makers in the most feasible and appropriate strategies for implementation.